Outset Medical, Inc. Research and Development Expense
Outset Medical, Inc. (OM) reported Research and Development Expense of $5.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Outset Medical, Inc. research and development expense for the quarter ending 2026-06-30 was $5.45M, a 3.04% increase year-over-year.
- Outset Medical, Inc. research and development expense for the quarter ending 2026-03-31 was $5.62M, a 1.87% increase year-over-year.
- Outset Medical, Inc. research and development expense for the quarter ending 2025-12-31 was $5.05M, a 35.92% decline year-over-year.
- Outset Medical, Inc. research and development expense for the quarter ending 2025-09-30 was $5.38M, a 33.95% decline year-over-year.
- Outset Medical, Inc. research and development expense for fiscal 2025 was $21.23M, a 44.70% decline from fiscal 2024.
- Outset Medical, Inc. research and development expense for fiscal 2024 was $38.40M, a 33.00% decline from fiscal 2023.
- Outset Medical, Inc. research and development expense for fiscal 2023 was $57.31M, a 17.30% increase from fiscal 2022.
- Outset Medical, Inc. research and development expense for fiscal 2022 was $48.85M, a 32.97% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.45M 10-Q · filed 2026-08-06 | $11.07M 10-Q · filed 2026-08-06 | $16.12M derived: sum of 3 quarters · filed 2026-08-06 | $21.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.62M 10-Q · filed 2026-05-07 | $10.67M derived: sum of 2 quarters · filed 2026-05-07 | $16.05M derived: sum of 3 quarters · filed 2026-05-07 | $21.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $10.43M derived: sum of 2 quarters · filed 2026-02-13 | $15.72M derived: sum of 3 quarters · filed 2026-08-06 | $21.23M 10-K · filed 2026-02-13 |
| 2025-09-30 | $5.38M 10-Q · filed 2025-11-10 | $10.66M derived: sum of 2 quarters · filed 2026-08-06 | $16.18M 10-Q · filed 2025-11-10 | $24.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.29M 10-Q · filed 2026-08-06 | $10.80M 10-Q · filed 2026-08-06 | $18.69M derived: sum of 3 quarters · filed 2026-08-06 | $26.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.51M 10-Q · filed 2026-05-07 | $13.40M derived: sum of 2 quarters · filed 2026-05-07 | $21.54M derived: sum of 3 quarters · filed 2026-05-07 | $31.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $16.03M derived: sum of 2 quarters · filed 2026-02-13 | $25.76M derived: sum of 3 quarters · filed 2026-02-13 | $38.40M 10-K · filed 2026-02-13 |
| 2024-09-30 | $8.14M 10-Q · filed 2025-11-10 | $17.87M derived: sum of 2 quarters · filed 2025-11-10 | $30.51M 10-Q · filed 2025-11-10 | $43.04M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $9.73M 10-Q · filed 2025-08-07 | $22.37M 10-Q · filed 2025-08-07 | $34.90M derived: sum of 3 quarters · filed 2026-02-13 | $50.98M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $12.63M 10-Q · filed 2025-05-08 | $25.17M derived: sum of 2 quarters · filed 2026-02-13 | $41.24M derived: sum of 3 quarters · filed 2026-02-13 | $56.15M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $12.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $28.61M derived: sum of 2 quarters · filed 2026-02-13 | $43.51M derived: sum of 3 quarters · filed 2026-02-13 | $57.31M 10-K · filed 2026-02-13 |
| 2023-09-30 | $16.08M 10-Q · filed 2024-11-07 | $30.98M derived: sum of 2 quarters · filed 2024-11-07 | $44.77M 10-Q · filed 2024-11-07 | $56.22M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $14.91M 10-Q · filed 2024-08-08 | $28.70M 10-Q · filed 2024-08-08 | $40.14M derived: sum of 3 quarters · filed 2025-02-28 | $53.20M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $13.79M 10-Q · filed 2024-05-09 | $25.24M derived: sum of 2 quarters · filed 2025-02-28 | $38.30M derived: sum of 3 quarters · filed 2025-02-28 | $51.82M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $11.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $24.50M derived: sum of 2 quarters · filed 2025-02-28 | $38.02M derived: sum of 3 quarters · filed 2025-02-28 | $48.85M 10-K · filed 2025-02-28 |
| 2022-09-30 | $13.06M 10-Q · filed 2023-11-08 | $26.58M derived: sum of 2 quarters · filed 2023-11-08 | $37.41M 10-Q · filed 2023-11-08 | $48.82M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $13.52M 10-Q · filed 2023-08-03 | $24.35M 10-Q · filed 2023-08-03 | $35.76M derived: sum of 3 quarters · filed 2024-02-21 | $45.49M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $10.83M 10-Q · filed 2023-05-04 | $22.24M derived: sum of 2 quarters · filed 2024-02-21 | $31.97M derived: sum of 3 quarters · filed 2024-02-21 | $40.00M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $11.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $21.14M derived: sum of 2 quarters · filed 2024-02-21 | $29.17M derived: sum of 3 quarters · filed 2024-02-21 | $36.74M 10-K · filed 2024-02-21 |
| 2021-09-30 | $9.73M 10-Q · filed 2022-11-09 | $17.76M derived: sum of 2 quarters · filed 2022-11-09 | $25.33M 10-Q · filed 2022-11-09 | $33.12M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-06-30 | $8.03M 10-Q · filed 2022-08-02 | $15.60M 10-Q · filed 2022-08-02 | $23.39M derived: sum of 3 quarters · filed 2023-02-13 | $32.56M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-03-31 | $7.57M 10-Q · filed 2022-05-05 | $15.35M derived: sum of 2 quarters · filed 2023-02-13 | $24.53M derived: sum of 3 quarters · filed 2023-02-13 | $30.58M derived: sum of 4 quarters · filed 2023-02-13 |
| 2020-12-31 | $7.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $16.96M derived: sum of 2 quarters · filed 2023-02-13 | $23.01M derived: sum of 3 quarters · filed 2023-02-13 | $28.85M 10-K · filed 2023-02-13 |
| 2020-09-30 | $9.18M 10-Q · filed 2021-11-04 | $15.23M derived: sum of 2 quarters · filed 2021-11-04 | $21.07M 10-Q · filed 2021-11-04 | $27.70M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $6.05M 10-Q · filed 2021-08-06 | $11.89M 10-Q · filed 2021-08-06 | $18.52M derived: sum of 3 quarters · filed 2022-02-23 | $24.23M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $5.84M 10-Q · filed 2021-05-06 | $12.47M derived: sum of 2 quarters · filed 2022-02-23 | $18.18M derived: sum of 3 quarters · filed 2022-02-23 | |
| 2019-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $12.34M derived: sum of 2 quarters · filed 2022-02-23 | $23.33M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $5.71M 10-Q · filed 2020-11-12 | $16.70M 10-Q · filed 2020-11-12 | ||
| 2018-12-31 | $22.92M 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Nuwellis, Inc. (NUWE) | United States | $0.003B |